"The Report Visudyne
(Macular Edema and Macular Degeneration) - Forecast and Market
Analysis to 2023 provides information on pricing, market analysis,
shares, forecast, and company profiles for key industry participants.
- MarketResearchReports.biz"
Description
Visudyne (Macular Edema and
Macular Degeneration) - Forecast and Market Analysis to 2023
Summary
Macular Edema is a condition
where fluid accumulates on the macula, leading to vision impairment
or in severe cases even vision loss. The three main types of ME are
diabetic macular edema (DME), and macular edema following either a
central or branch retinal vein occlusion (ME-CRVO and ME-BRVO).
Age-related macular degeneration (AMD) is a painless eye condition
which leads to gradual, irreversible, loss of central vision, and is
one of the leading causes of blindness among people aged 50 and over
in the developed world. Currently the ME and AMD markets are
dominated by the use of anti-VEGF monotherapy, however, in recent
years, corticosteroid implants have been reaching the ME market which
could challenge the stronghold these drugs have in this sector. The
AMD market will see the arrival of the first therapies to treat dry
AMD, fulfilling a huge unmet need in the management of this retinal
disease, and these first-in-class therapies will strongly drive the
market growth over the next ten years. The launch of wet AMD
adjunctive therapies will also see a significant change in the
treatment of AMD patients and have a positive impact on the market
growth.
Visudyne (verteporfin) is a
photosensitizer molecule that was co-developed by QLT
PhotoTherapeutics and Novartis Pharma AG for use in a two-step
procedure involving the use of a non-thermal laser light, known as
PDT. It was initially approved by the FDA in April 2000 for the
treatment of patients with predominantly classical subfoveal CNV due
to AMD.
View
Full Report at http://www.marketresearchreports.biz/analysis/247092
Scope
- Overview of Macular Edema
and Macular Degeneration, including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview
on the competitive landscape.
- Detailed information on
Visudyne including product description, safety and efficacy profiles
as well as a SWOT analysis.
- Sales forecast for Visudyne
for the top seven countries from 2013 to 2023.
- Sales information covered
for the US, France, Germany, Italy, Spain, the UK and Japan
Reasons
to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return.
- Stay ahead of the
competition by understanding the changing competitive landscape for
Macular Edema and Macular Degeneration.
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential.
- Make more informed business
decisions from insightful and in-depth analysis of Visudyne
performance.
- Obtain sales forecast for
Visudyne from 2013-2023 in top seven countries (the US, France,
Germany, Italy, Spain, the UK and Japan).
Download
Detail Report With Complete TOC at
Table
of Content
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Related Reports 10
3 Disease Overview 12
3.1 Macular Degeneration
Overview 12
3.1.1 Etiology and
Pathophysiology 14
3.1.2 Classification 18
3.1.3 Symptoms and Diagnosis
20
3.2 Macular Edema Overview 23
3.2.1 Etiology and
Pathophysiology 24
3.2.2 Classification 27
3.2.3 Symptoms and Diagnosis
28
4 Disease Management 31
4.1 Diagnosis and Treatment
Overview 31
4.1.1 Macular Edema Diagnosis
31
4.1.2 Macular Degeneration
Diagnosis 31
4.1.3 Treatment Guidelines and
Leading Prescribed Drugs 32
4.1.4 Clinical Practice 34
5 Competitive Assessment 48
5.1 Overview 48
6 Visudyne (verteporfin) 50
6.1 Overview 50
6.2 Efficacy - Macular
Degeneration 52
6.3 Safety 53
6.4 SWOT Analysis 53
6.5 Forecast 54
7 Appendix 55
Browse
Latest News at http://www.marketresearchreports.biz/articles
About
Us
MarketResearchReports.biz is
the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Browse
Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz
Contact
Us
Office:
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA: Canada Toll Free:
866-997-4948
No comments:
Post a Comment